What is enenfusion (ENFN) stock price?
Enfusion Inc. ENFN, is set for its public debut Thursday, as the Chicago-based investment management software company's initial public offering priced overnight at $17 a share, at the top of the expecte...
Where can I buy Enfusion shares?
Shares of ENFN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enfusion's stock price today?
What was enenfusion’s IPO price on Wall Street?
Enfusion Inc. ENFN, +20.15% was well received on its Wall Street debut, as the Chicago-based investment management software company's stock opened 17.6% above its IPO price. The company raised $260.5 mi...
What is the ticker symbol for Enfusion?
Enfusion trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENFN." When did Enfusion's lock-up period expire? Enfusion's lock-up period expired on Tuesday, April 19th. Enfusion had issued 18,750,000 shares in its public offering on October 21st.
Is Enfusion a good stock to buy?
Enfusion has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Is Enfusion a public company?
("Enfusion"), a leading provider of cloud-based investment management software and services, today announced the pricing of its initial public offering of 15,322,660 shares of its Class A common stock offered by Enfusion and 3,427,340 shares of Class A common stock to be sold by certain of Enfusion's existing ...
What does Enfusion company do?
Enfusion LLC provides software solutions. The Company offers software-as-a-service platform that allows clients to see and interact with all parts of the investment management lifecycle ranging from portfolio construction, trading, risk management, accounting, and operations.
Is Enfusion a Fintech company?
As a Fintech leader and pioneer in developing innovative solutions, Enfusion partners with 600+ investment managers from nine global offices spanning four continents.
Should I buy or sell Enfusion stock right now?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 hold ratings and 4 buy ra...
What is Enfusion's stock price forecast for 2022?
7 brokerages have issued 12-month price objectives for Enfusion's shares. Their forecasts range from $15.00 to $20.00. On average, they expect Enfu...
How has Enfusion's stock performed in 2022?
Enfusion's stock was trading at $20.94 at the beginning of 2022. Since then, ENFN shares have decreased by 51.5% and is now trading at $10.16. Vie...
When is Enfusion's next earnings date?
Enfusion is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Enfusion .
How were Enfusion's earnings last quarter?
Enfusion, Inc. (NYSE:ENFN) issued its quarterly earnings data on Thursday, March, 24th. The company reported $0.55 earnings per share (EPS) for the...
What guidance has Enfusion issued on next quarter's earnings?
Enfusion issued an update on its second quarter 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share guidance of...
Who are Enfusion's key executives?
Enfusion's management team includes the following people: Mr. Thomas Kim , CEO & Director (Age 49) Mr. Stephen Malherbe , Managing Partner Mr....
Who are some of Enfusion's key competitors?
Some companies that are related to Enfusion include Coupa Software (COUP) , National Instruments (NATI) , Paycor HCM (PYCR) , BlackLine (BL) ,...
When did Enfusion IPO?
(ENFN) raised $300 million in an initial public offering (IPO) on Thursday, October 21st 2021. The company issued 18,750,000 shares at a price of $...
Is Enfusion stock a Buy, Sell or Hold?
Enfusion stock has received a consensus rating of hold. The average rating score is and is based on 4 buy ratings, 10 hold ratings, and 0 sell rati...
What was the 52-week low for Enfusion stock?
For Enfusion stock is no 52WeekLow data available or the value couldn't be calculated because of a value to close/at 0.00.
What was the 52-week high for Enfusion stock?
For Enfusion stock is no 52WeekHigh data available or the value couldn't be calculated because of a value to close/at 0.00.
What are analysts forecasts for Enfusion stock?
The 14 analysts offering price forecasts for Enfusion have a median target of 21.64, with a high estimate of 30.00 and a low estimate of 8.00. The...
About ENFN
Analyst Forecast
Enfusion is a global, high-growth software-as-a-service provider focused on transforming the investment management industry. Our solution is designed to eliminate technology and information barriers, empowering investment managers to confidently make and execute better-informed investment decisions in real time.
News
According to 7 analysts, the average rating for Enfusion stock is "Buy." The 12-month stock price forecast is 25.67, which is an increase of 83.49% from the latest price.
About Enfusion
NEW YORK & LONDON & HONG KONG-- (BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of cloud-based investment management software and services, today announced two internal exec...
Headlines
Enfusion Inc. is a provider of cloud-based investment management software and services. Through its software, analytics and middle/back-office managed services, it creates enterprise-wide cultures of real-time, data-driven intelligence, boosting agility and powering growth. Enfusion Inc. is based in NEW YORK.
Enfusion (NYSE:ENFN) Frequently Asked Questions
Should You Consider Investing for the Long-Term in Enfusion Inc. (ENFN)?
Premium Research for ENFN
7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enfusion in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock.
Company Summary
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
